title: Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
abstract: OBJECTIVE
  the aim of this paper was to review the initial use of Palifermin(rHu-KGF1) in a single institution, for the prevention of oral mucositis in high-dose chemotherapy and stem cell transplantation.
  
  
  METHODS
  the case records of the first five patients treated with Palifermin at the Royal Adelaide Hospital Cancer Centre were reviewed, and incidence,severity and duration of the oral mucositis were recorded, as well as demographics and toxicities.
  
  
  RESULTS
  two of the five patients developed grade 4 mucositis, and the remaining three patients developed grade 2 mucositis. Palifemin was well tolerated with only one patient developing a rash.
  
  
  CONCLUSIONS
  the severity of oral mucositis was less than would be expected in these patients without anti-mucositis therapy. Palifermin was well tolerated. Obviously this single institution report is from a very small cohort of patients, but it is encouraging for the ease of use of this drug in the future.
authors.affiliation: Department of Medical Oncology, Royal Adelaide Hospital Cancer Centre, Adelaide, South Australia.
authors.forename: Dorothy
authors.initials: D
authors.lastname: Keefe
authors.forename: Jude
authors.initials: J
authors.lastname: Lees
authors.forename: Noemi
authors.initials: N
authors.lastname: Horvath
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002066:Busulfan / Q000009:adverse effects; D002173:Cancer Care Facilities; D002330:Carmustine / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D008297:Male; D008558:Melphalan / Q000009:adverse effects; D008875:Middle Aged; D011034:Podophyllotoxin / Q000009:adverse effects; D011322:Primary Prevention; D012720:Severity of Illness Index; D013021:South Australia / Q000453:epidemiology; D013280:Stomatitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D051523:Fibroblast Growth Factor 7; D003520:Cyclophosphamide; D002066:Busulfan; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine